Clin Chem:Zika病毒特异性IgM抗体

2019-07-20 gladiator MedSci原创

既往研究表明,细胞表面分子<span lang="EN-US" style="font-size:12.0pt;mso-bidi-font-size:14.0pt;font-family:"Calibri","sans-serif"; mso-fareast-font-family:宋体;mso-bidi-font-family:"Times N

既往研究表明,细胞表面分子HsTOSO / FAIM3 /HsFcμR是在淋巴细胞上表达的IgM特异性Fc受体。本研究显示其细胞外免疫球蛋白样结构域(HsFcμR-Igl)可以和IgM /抗原免疫复合物(IC)特异性结合,并利用这一特性开发针对克里米亚-刚果出血热病毒和寨卡病毒(ZIKV)的IgM抗体的新型检测系统( CCHFV)。

研究人员在大肠杆菌表达His-tagged HsFcμR-Igl,并通过亲和色谱法、氧化重折叠及凝胶排阻层析法纯化。确认HsFcμR-Ig1IgM /抗原IC的特异性结合,并开发了用于检测抗CCHFV和抗ZIKV IgM抗体的2种原型ELISA。因此,直接用辣根过氧化物酶(HRP)标记的患者血清和病毒特异性重组抗原在HsFcμR-Ig1包被的ELISA板上共孵育。通过测量显色HRP底物的转换来对结合的IC进行定量。

研究人员对15例经PCR证实的科索沃CCHFV感染患者和28例经PCR证实的巴西ZIKV感染患者的配对血清样本,以及一组CCHFV/ZIKV- igm阴性血清样本进行了检测验证。两种ELISAs都具有很高的可重复性。敏感性和特异性可与公司内部的黄金标准测试和商业试剂盒相媲美,甚至超过商业试剂盒。此外,涂有HsFcμR-Ig1的乳胶珠在与IgM阳性血清和HRP标记的抗原共孵育时聚集,但不与任一组分单独聚集,揭示了在基于聚集的快速测试中使用HsFcμR-Ig1作为捕获分子的潜力。

研究表明,重组HsFcμR-Ig1是用于人和动物来源的IgM /抗原IC的通用捕获分子,并且在将来可以用于基于平板和珠子的血清学测试的开发。

原始出处:

Anne Rackow, Christa Ehmen,Immunoglobulin-like Domain of HsFcμR as a Capture Molecule for Detection of Crimean-Congo Hemorrhagic Fever Virus- and Zika Virus-Specific IgM Antibodies

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1738186, encodeId=da2f1e381864b, content=<a href='/topic/show?id=1d66190426d' target=_blank style='color:#2F92EE;'>#Zika#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19042, encryptionId=1d66190426d, topicName=Zika)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8ae34370737, createdName=新生儿张玉军, createdTime=Sat Feb 08 00:20:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899309, encodeId=32571899309ff, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Tue Aug 13 05:20:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700378, encodeId=93fe1e003787f, content=<a href='/topic/show?id=a40c9525be' target=_blank style='color:#2F92EE;'>#IgM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9525, encryptionId=a40c9525be, topicName=IgM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e80a30065003, createdName=yhy100210, createdTime=Sun Dec 22 20:20:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575263, encodeId=763c15e5263da, content=<a href='/topic/show?id=11f119043fb' target=_blank style='color:#2F92EE;'>#Zika病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19043, encryptionId=11f119043fb, topicName=Zika病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa2316073552, createdName=ying_wu, createdTime=Mon Jul 22 14:20:00 CST 2019, time=2019-07-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1738186, encodeId=da2f1e381864b, content=<a href='/topic/show?id=1d66190426d' target=_blank style='color:#2F92EE;'>#Zika#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19042, encryptionId=1d66190426d, topicName=Zika)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8ae34370737, createdName=新生儿张玉军, createdTime=Sat Feb 08 00:20:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899309, encodeId=32571899309ff, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Tue Aug 13 05:20:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700378, encodeId=93fe1e003787f, content=<a href='/topic/show?id=a40c9525be' target=_blank style='color:#2F92EE;'>#IgM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9525, encryptionId=a40c9525be, topicName=IgM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e80a30065003, createdName=yhy100210, createdTime=Sun Dec 22 20:20:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575263, encodeId=763c15e5263da, content=<a href='/topic/show?id=11f119043fb' target=_blank style='color:#2F92EE;'>#Zika病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19043, encryptionId=11f119043fb, topicName=Zika病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa2316073552, createdName=ying_wu, createdTime=Mon Jul 22 14:20:00 CST 2019, time=2019-07-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1738186, encodeId=da2f1e381864b, content=<a href='/topic/show?id=1d66190426d' target=_blank style='color:#2F92EE;'>#Zika#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19042, encryptionId=1d66190426d, topicName=Zika)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8ae34370737, createdName=新生儿张玉军, createdTime=Sat Feb 08 00:20:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899309, encodeId=32571899309ff, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Tue Aug 13 05:20:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700378, encodeId=93fe1e003787f, content=<a href='/topic/show?id=a40c9525be' target=_blank style='color:#2F92EE;'>#IgM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9525, encryptionId=a40c9525be, topicName=IgM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e80a30065003, createdName=yhy100210, createdTime=Sun Dec 22 20:20:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575263, encodeId=763c15e5263da, content=<a href='/topic/show?id=11f119043fb' target=_blank style='color:#2F92EE;'>#Zika病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19043, encryptionId=11f119043fb, topicName=Zika病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa2316073552, createdName=ying_wu, createdTime=Mon Jul 22 14:20:00 CST 2019, time=2019-07-22, status=1, ipAttribution=)]
    2019-12-22 yhy100210
  4. [GetPortalCommentsPageByObjectIdResponse(id=1738186, encodeId=da2f1e381864b, content=<a href='/topic/show?id=1d66190426d' target=_blank style='color:#2F92EE;'>#Zika#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19042, encryptionId=1d66190426d, topicName=Zika)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8ae34370737, createdName=新生儿张玉军, createdTime=Sat Feb 08 00:20:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899309, encodeId=32571899309ff, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Tue Aug 13 05:20:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700378, encodeId=93fe1e003787f, content=<a href='/topic/show?id=a40c9525be' target=_blank style='color:#2F92EE;'>#IgM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9525, encryptionId=a40c9525be, topicName=IgM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e80a30065003, createdName=yhy100210, createdTime=Sun Dec 22 20:20:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575263, encodeId=763c15e5263da, content=<a href='/topic/show?id=11f119043fb' target=_blank style='color:#2F92EE;'>#Zika病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19043, encryptionId=11f119043fb, topicName=Zika病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa2316073552, createdName=ying_wu, createdTime=Mon Jul 22 14:20:00 CST 2019, time=2019-07-22, status=1, ipAttribution=)]

相关资讯

CDC:感染Zika病毒的男性需等6个月才能进行无保护措施的性活动

美国卫生当局称:感染Zika病毒或有Zika病毒感染症状的男性,应该至少等6个月,才能进行无保护措施的性活动。美国疾病控制和预防中心(CDC)更新了针对Zika病毒爆发之际,确保母婴安全的临时指南:感染Zika病毒或有Zika病毒感染症状的女性,应该至少等8周时间,才能尝试妊娠。不打算怀孕的夫妇也应该等待相同的时间才能进行性活动。当前关于Zika病毒我们已经认识到,感染该病毒的孕妇产下小头畸形新生

NEJM:哥伦比亚Zika的初步报告:孕晚期感染Zika病毒与胎儿结构异常无关

哥伦比亚对Zika病毒病(ZVD)的官方监测始于2015年8月,当实验室确诊9例ZVD后,于2015年10月宣布ZVD爆发。研究者基于国家人口为基础的监控系统,评估了2015年8月9日-2016年4月2日的ZVD患者临床症状,对孕妇评估了实验室检查结果和妊娠结局,同时调查报告先天性ZVD的证据小头畸形。截止016年4月2日,哥伦比亚报道了65726例ZVD,其中2485例(4%)通过逆转录酶–聚合

Am J Med Genet A:先天性Zika综合征是什么样的?

【如何预防和改善ZIKV的作用】疾病控制中心报告说:“Zika病毒变得越来越流行,出生就是小头症或其他出生缺陷的美国婴儿的数量是正常率的20倍,研究人员仍在试图确定病毒识别结果感染。本周在美国医学遗传学杂志上发表的一篇新文章中,第一作者Miguel del Campo博士,加利福尼亚大学圣地亚哥分校医学院儿科系副教授,以及巴西和西班牙的同事,描述基于对推测或确认的ZIKV先天性感染的83名巴西儿童

BMJ:ZIKA病毒感染与新生儿结局

研究认为在已知产妇ZIKA病毒感染的情况下,大约四分之一的胎儿存在先天感染,其中三分之一的胎儿在出生时会出现严重并发症或胎儿丢失

Cell Reports:感染Zika病毒,对眼睛有什么危害?

研究人员评估Zika病毒感染眼睛时的小鼠研究显示:Zika病毒可以感染小鼠的角膜、虹膜、视网膜和视神经,引起结膜炎、葡萄膜炎、视神经视网膜炎。 使用抗lfnar1阻断抗体和皮下接种低传代Zika病毒,这些病毒来自法属波利尼西亚和巴西。 研究人员对接种后28天的小鼠进行了评估。他们发现,当血清中病毒被清楚后,以下几个组织仍存在Zika (ZIKV) RNA:包括眼、脑、脾等器官。

首例Zika病毒经性传播由女性传染给男性的报道

纽约市健康与心理卫生局(DOHMH)15日报告了首例通过性传播由女性传染寨卡病毒给男性的报道。CDC更新了关于公众如何应对此健康威胁的建议。 截至目前,之前所有报道寨卡病毒经性传播的,都是男性传染给女性。 根据CDC最新发布的《发病率和死亡率周报》(MMWR),DOHMH 证实了纽约一名20多岁未孕女性,在寨卡流行区回国后与男性伴侣进行无保护阴道性交(第0天),第1天就开始出现寨卡病毒